Options X Conference | Singapore
The 10th Options for the Control of Influenza (Options X) conference featured a dialogue co-hosted by Sabin and Flu Lab with representatives of industry, government, universities and philanthropy.
Participants explored the role of interdisciplinary discussions, data sharing and flexible and targeted funding in universal influenza vaccine development.
A Call to Action Meeting | London
The Influenzer Initiative, hosted by the Wellcome Trust, engaged cross-disciplinary researchers, industry representatives, investors and policy thought leaders around engaging cutting-edge science and technology methods and talent to drive UIV breakthroughs.
Building on these insights, Sabin’s funding partner, Flu Lab, launched a platform to boost research collaboration and encourage replication of influenza research findings.
Sabin-Aspen Vaccine Science and Policy Group Meeting | Aspen, CO
The Sabin-Aspen Vaccine Science & Policy Group convened influential, out-of-the-box thinkers across scientific, medical, business and regulatory disciplines to vigorously probe the urgent need to eliminate the persistent threat of influenza.
Following the meeting, the Group put forth its inaugural report advancing three actionable “Big Ideas” to accelerate a next-generation influenza vaccine.
If we could develop an effective next-generation vaccine that gives even three to five years of protection, it would be a major step forward–particularly for the countries that experience the greatest burden of influenza, and especially for vulnerable people including pregnant women and young children.Rebecca Cox, Professor of Virology, University of Bergen; Head of the Influenza Centre, Department of Clinical Science